PHOENIX, AZ--(Marketwire - February 02, 2012) - Kedem Pharmaceuticals Inc. (OTCBB: KDMP), a specialty pharmaceutical company with focus on sublingual drug delivery, is pleased to announce the company CEO Dr. Hassan Salari providing an update on the company's progress on YouTube for the Company's lead therapeutic drug for erectile dysfunction X-Excite. The Company's second lead therapeutic drug KDM-1102 is a new sublingual formulation of Propanolol. The newest drug initiated into development is Gleevec®. Gleevec® is an important anti-cancer drug for the treatment of several blood related cancers in children and adults.
"We were pleased to provide a shareholder update via a taped interview on YouTube and are excited to have a platform for review by the investment community. The video interview allows us to go into more detail about our goals to commercialize our sublingual drug delivery system," expressed Dr. Hassan Salari, PhD, CEO.
Interview of Dr. Hassan Salari, CEO click link: http://www.youtube.com/watch?v=lmb3mUVVPu4
Corporate Fact Sheet: http://kedempharmaceuticals.com/images/kedem%20fact%20sheet%20-1.pdf
About Sublingual Technology
The Company's sublingual formulation is designed to enhance drugs to be delivered to the body without the need for injection. This design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane (tissues of the mouth) quickly and efficiently. This technology works well for drugs that need faster results and have major side effects associated with gastrointestinal and/or liver breakdown. It is scientifically accepted that sublingual drug delivery route is the fastest and most efficient way of drug delivery after direct injection. The technology may apply to over 40 major drugs which all can benefit from this route.
Kedem Pharmaceuticals Inc. (OTCBB: KDMP) is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. The Company has several other drugs under development for fast and convenient delivery. These include drugs for anxiety attack, osteoporosis, sleeping disorders, pain killers, migraine, anti-allergy medications, cardiovascular diseases, lung medications, and addiction replacement therapies.
This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Additionally this press release includes statements within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to high risks, uncertainties and other factors, including that the Regulatory Agencies may not agree to the claims made in the Company documents related to our products, and product development. There are risks that due to unforeseen reasons, matters could cause the actual results to differ materially from those referred in our fillings. Risks involved patent infringement, trademark and other commercially related actions that hinder the product development and marketing. Additional risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission, as well as to obtain independent third party opinions before investing in the Company's securities.